evolved, striving for improved performance and better outcomes. 8 – 10 Although broadly implemented, CPR is most beneficial for acute, potentially reversible causes of cardiopulmonary arrest and should not be performed on patients with terminal or
Search Results
Sanjay Chawla, Cristina Gutierrez, Prabalini Rajendram, Kenneth Seier, Kay See Tan, Kara Stoudt, Marian Von-Maszewski, Jorge L. Morales-Estrella, Natalie T. Kostelecky, and Louis P. Voigt
Leslie R. Schover, Ying Yuan, Bryan M. Fellman, Evan Odensky, Pamela E. Lewis, and Paul Martinetti
card on completing questionnaires at each follow-up. Items assessed background and medical history. The FSFI was the primary outcome measure. 29 The FSFI is a 19-item, multiple-choice questionnaire with excellent internal consistency, discriminant
Myron Goldsmith, George Whitelaw, and Denise A. Cannaday
Venous thromboembolism (VTE) is still the most common preventable cause of hospital death, with cancer a known significant risk factor for its development. Prophylaxis to prevent VTE in hospitalized surgical and medical patients has been suboptimal, and efforts for improvement have been unsuccessful. Recent practice guidelines on VTE in oncology from the National Comprehensive Cancer Network and American Society of Clinical Oncologists have further highlighted this relationship and could bridge performance measures and outcomes that can affect the strategies for preventing deep venous thrombosis and pulmonary embolism in oncology patients. Hospitals and physicians with poor performance data will have problems with payment from the Centers for Medicare & Medicaid Services and contracting the best rates from other payors. Hospital accreditation from The Joint Commission could be an issue for poorly performing institutions, as could consumer acceptance. The authors believe that specific oncology VTE measures should be developed to help decrease the current poor rates of VTE prophylaxis and also improve hospital and physician compliance.
Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia
ribociclib and subsequently received abemaciclib-based therapy. We report on the treatment patterns of continued CDK4/6i therapy across 6 institutions, the clinical outcome data, the toxicity experience with a second course of CDK4/6i, and emerging insights
Daniëlle D. Huijts, Onno R. Guicherit, Jan Willem T. Dekker, Julia T. van Groningen, Leti van Bodegom-Vos, Esther Bastiaannet, Johannes A. Govaert, Michel W. Wouters, and Perla J. Marang-van de Mheen
performed on a Friday. However, these studies showing worse outcomes after Friday surgeries may be limited because of their use of administrative data, which are known to be susceptible to insufficient adjustment for case mix. 9 As a result, worse outcomes
Linda Overholser and Carlin Callaway
Oncology, University of Colorado School of Medicine, who discussed the importance of care coordination to optimize health outcomes in cancer survivors at the NCCN 2019 Annual Conference, achieving coordinated, patient-centered care will require effective
Brooke E. Wilson, Sallie-Anne Pearson, Michael B. Barton, and Eitan Amir
ability to test treatments across different populations with unique attributes, genetics, and ethnicity. When pooling outcomes across regions and countries, studies assume that treatment effects are similar. However, even among high-income countries with
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich
Background Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. 1 Although ICIs have improved outcomes in several cancers, their use is also
Gary H. Lyman and David C. Dale
M yeloid growth factors have been used for more than 20 years to ameliorate myelotoxicity after cancer chemotherapy and to prevent infections in patients with chronic neutropenia. Almost all data on long-term outcomes come from studies of
David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser
National Surgical Quality Improvement Project (NSQIP). In general, each program follows the Donabedian 4 , 5 paradigm for measuring health care quality with respect to 1 of 3 domains: structure, process, and outcomes. Although limitations exist with each
